Section

Bookeeping tables during data processing

ID before and after main file
Before After
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
62 62
63 63
64 64
65 65
66 66
67 67
68 68
69 69
70 70
71 71
72 72
73 73
74 74
75 75
76 76
77 77
78 78
79 79
80 80
81 81
82 82
83 83
84 84
85 85
86 86
87 87
88 88
89 89
90 90
91 91
92 92
93 93
94 94
95 95
96 96
97 97
98 98
99 99
100 100
101 101
102 102
103 103
104 104
105 105
106 106
AAL-01 AAL1
AAL-02 AAL2
AAL-03 AAL3
AAL-04 AAL4
AAL-05 AAL5
USC-52 USC52
USC-53 USC53
USC-54 USC54
USC-55 USC55
USC-56 USC56
USC-57 USC57
USC-59 USC59
USC-60 USC60
ID before and after VAFS file
Before After
23-1-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S84 23
23-1-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S84 23
23-2-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S85 23
23-2-ML_EVI-pool-16_230329_A01961_AHMCGTDRX2_S85 23
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82 26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82 26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82 26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82 26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82 26
26-1-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S82 26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83 26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83 26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83 26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83 26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83 26
26-5-BM_EVI-pool-15_230329_A01961_AHMCGTDRX2_S83 26
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90 35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90 35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90 35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90 35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90 35
35-1-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S90 35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91 35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91 35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91 35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91 35
35-5-LM_EVI-pool-16_230329_A01961_AHMCGTDRX2_S91 35
1-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S131 1
1-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S131 1
1-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S131 1
1-2-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S132 1
1-2-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S132 1
1-2-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S132 1
3-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S33 3
3-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S33 3
3-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S34 3
3-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S34 3
3-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S34 3
7-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S121 7
7-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S121 7
7-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S122 7
7-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S122 7
7-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S122 7
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S123 8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124 8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124 8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124 8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124 8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124 8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124 8
8-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S124 8
10-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S63 10
10-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S63 10
10-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S63 10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64 10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64 10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64 10
10-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S64 10
11-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S35 11
11-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S36 11
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37 12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37 12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37 12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37 12
12-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S37 12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38 12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38 12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38 12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38 12
12-2-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S38 12
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39 13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39 13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39 13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39 13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39 13
13-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S39 13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40 13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40 13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40 13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40 13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40 13
13-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S40 13
15-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S125 15
15-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S125 15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126 15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126 15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126 15
16-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S41 16
16-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S41 16
16-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S42 16
16-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S42 16
16-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S42 16
18-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S127 18
18-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S127 18
18-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S128 18
18-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S128 18
19-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S43 19
19-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S43 19
19-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S43 19
19-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S44 19
19-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S44 19
19-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S44 19
20-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S65 20
20-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S65 20
20-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S66 20
20-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S66 20
20-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S66 20
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67 22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67 22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67 22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67 22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67 22
22-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S67 22
22-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S68 22
22-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S68 22
22-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S68 22
27-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S45 27
27-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S46 27
28-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S1 28
28-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S1 28
28-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S2 28
28-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S2 28
29-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S47 29
29-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S47 29
29-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S47 29
29-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S48 29
29-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S48 29
29-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S48 29
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71 31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71 31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71 31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71 31
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71 31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72 31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72 31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72 31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72 31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72 31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72 31
32-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S79 32
33-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S3 33
33-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S4 33
34-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S80 34
34-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S80 34
34-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S81 34
34-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S81 34
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49 36
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49 36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50 36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50 36
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115 37
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115 37
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115 37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116 37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116 37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116 37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116 37
39-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S93 39
39-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S94 39
40-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S133 40
40-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S134 40
40-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S134 40
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95 41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95 41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95 41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95 41
41-1-PBMC-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S95 41
41-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S96 41
41-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S96 41
41-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S96 41
43-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S82 43
44-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S5 44
44-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S5 44
44-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S6 44
44-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S6 44
46-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S129 46
46-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S130 46
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7 47
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7 47
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7 47
47-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S7 47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8 47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8 47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8 47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8 47
47-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S8 47
48-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S83 48
48-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S83 48
49-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S97 49
49-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S98 49
50-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S99 50
50-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S100 50
50-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S100 50
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101 51
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101 51
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101 51
51-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S101 51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102 51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102 51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102 51
51-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S102 51
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103 64
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103 64
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103 64
64-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S103 64
64-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S104 64
64-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S104 64
64-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S104 64
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84 67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84 67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84 67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84 67
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84 67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85 67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85 67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85 67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85 67
68-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S9 68
68-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S9 68
68-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S10 68
68-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S10 68
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S11 69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12 69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12 69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12 69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12 69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12 69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12 69
69-5-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S12 69
72-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S51 72
72-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S52 72
74-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S13 74
74-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S13 74
74-1-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S13 74
74-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S14 74
74-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S14 74
74-2-CD34-CMPv3_EVI-pool-35_240513_A01176_BHGKWCDRX3_S14 74
76-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S87 76
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15 78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15 78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15 78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15 78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15 78
78-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S15 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
78-4-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S16 78
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17 81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17 81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17 81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17 81
81-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S17 81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18 81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18 81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18 81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18 81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18 81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18 81
81-2-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S18 81
83-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S19 83
83-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S19 83
83-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S19 83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20 83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20 83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20 83
83-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S20 83
84-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S21 84
84-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S21 84
84-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S22 84
84-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S22 84
86-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S23 86
86-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S23 86
86-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S24 86
86-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S24 86
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88 87
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88 87
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88 87
87-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S88 87
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25 89
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25 89
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25 89
89-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S25 89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26 89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26 89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26 89
89-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S26 89
94-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S27 94
94-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S28 94
97-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S53 97
97-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S53 97
97-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S53 97
97-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S54 97
97-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S54 97
97-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S54 97
98-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S29 98
98-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S29 98
98-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S29 98
98-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S30 98
98-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S30 98
98-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S30 98
100-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S31 100
100-1-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S31 100
100-5-CD34-CMPv3_EVI-pool-37_240513_A01176_BHGKWCDRX3_S32 100
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111 103
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111 103
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111 103
103-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S111 103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112 103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112 103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112 103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112 103
103-2-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S112 103
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113 104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113 104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113 104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113 104
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113 104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114 104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114 104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114 104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114 104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114 104
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119 105
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119 105
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119 105
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119 105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120 105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120 105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120 105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120 105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120 105
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55 106
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55 106
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55 106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56 106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56 106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56 106
AAL1-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S117 AAL1
AAL1-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S117 AAL1
AAL1-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S117 AAL1
AAL1-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S118 AAL1
AAL1-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S118 AAL1
AAL1-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S118 AAL1
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57 AAL2
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57 AAL2
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57 AAL2
AAL2-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S57 AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58 AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58 AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58 AAL2
AAL2-2-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S58 AAL2
AAL3-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S59 AAL3
AAL3-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S60 AAL3
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135 AAL4
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135 AAL4
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135 AAL4
AAL4-1-CD34-EVI-pool-34_240513_A01176_BHGKWCDRX3_S135 AAL4
AAL5-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S61 AAL5
AAL5-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S61 AAL5
AAL5-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S62 AAL5
AAL5-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S62 AAL5
USC52-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S105 USC52
USC52-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S105 USC52
USC52-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S105 USC52
USC52-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S106 USC52
USC52-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S106 USC52
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107 USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107 USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107 USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107 USC53
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107 USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108 USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108 USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108 USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108 USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108 USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108 USC53
2-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S1 2
2-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S2 2
4-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S3 4
4-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S4 4
4-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S4 4
5-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S5 5
5-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S5 5
5-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S6 5
5-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S6 5
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7 6
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7 6
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7 6
6-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S7 6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8 6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8 6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8 6
6-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S8 6
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9 9
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9 9
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9 9
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9 9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10 9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10 9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10 9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10 9
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13 17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13 17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13 17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13 17
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13 17
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14 21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14 21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14 21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14 21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14 21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14 21
21-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S14 21
24-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S15 24
24-1-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S15 24
24-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S16 24
24-5-BMGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S16 24
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17 25
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17 25
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17 25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18 25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18 25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18 25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18 25
38-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S19 38
38-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S20 38
42-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S23 42
42-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S24 42
45-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S25 45
45-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S25 45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26 45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26 45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26 45
62-1-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S27 62
62-1-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S27 62
62-5-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S28 62
62-5-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S28 62
63-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S29 63
63-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S30 63
65-1-CD34Pos-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S31 65
65-2-CD34Pos-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S32 65
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33 66
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33 66
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33 66
66-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S33 66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34 66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34 66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34 66
66-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S34 66
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35 70
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35 70
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35 70
70-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S35 70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36 70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36 70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36 70
70-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S36 70
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37 71
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37 71
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37 71
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37 71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38 71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38 71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38 71
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39 73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39 73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39 73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39 73
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39 73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40 73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40 73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40 73
75-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S41 75
75-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S41 75
75-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S42 75
75-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S42 75
77-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S43 77
77-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S44 77
79-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S45 79
79-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S45 79
79-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S45 79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46 79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46 79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46 79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46 79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46 79
79-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S46 79
80-1-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S47 80
80-1-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S47 80
80-5-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S48 80
80-5-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S48 80
82-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S50 82
85-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S51 85
85-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S52 85
88-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S53 88
88-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S53 88
88-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S53 88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54 88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54 88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54 88
88-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S54 88
90-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S55 90
90-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S56 90
91-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S57 91
91-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S57 91
91-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S57 91
91-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S58 91
91-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S58 91
91-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S58 91
92-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S59 92
92-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S59 92
92-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S60 92
92-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S60 92
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61 93
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61 93
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61 93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62 93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62 93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62 93
95-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S63 95
95-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S63 95
95-1-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S63 95
95-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S64 95
95-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S64 95
95-5-CD34Pos-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S64 95
99-1-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S67 99
99-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S68 99
102-1-PBGran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S70 102
102-5-PBGran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S71 102
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72 AAL4
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72 AAL4
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72 AAL4
AAL4-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S72 AAL4
USC54-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S73 USC54
USC54-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S73 USC54
USC54-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S73 USC54
USC54-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S74 USC54
USC54-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S74 USC54
USC54-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S74 USC54
USC55-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S75 USC55
USC55-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S76 USC55
USC56-1-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S77 USC56
USC56-5-CD34Pos-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S78 USC56
USC57-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S79 USC57
USC57-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S79 USC57
USC57-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S80 USC57
USC57-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S80 USC57
USC59-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S81 USC59
USC59-1-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S81 USC59
USC59-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S82 USC59
USC59-5-Gran-CMPv3_EVI2-pool-46_241111_A00559_AHF5FFDRX5_S82 USC59
15-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S125 15
15-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S126 15
30-1-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S69 30
30-5-CD34-CMPv3_EVI-pool-39_240513_A01176_BHGKWCDRX3_S70 30
31-1-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S71 31
31-5-CD34-CMPv3_EVI-pool-40_240513_A01176_BHGKWCDRX3_S72 31
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49 36
36-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S49 36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50 36
36-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S50 36
37-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S115 37
37-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S116 37
46-1-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S129 46
46-5-CD34-CMPv3_EVI-pool-34_240513_A01176_BHGKWCDRX3_S130 46
50-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S99 50
50-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S100 50
67-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S84 67
67-5-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S85 67
76-1-CD34-CMPv3_EVI-pool-41_240513_A01176_BHGKWCDRX3_S87 76
84-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S21 84
84-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S22 84
94-1-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S27 94
94-5-CD34-CMPv3_EVI-pool-36_240513_A01176_BHGKWCDRX3_S28 94
101-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S109 101
101-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S110 101
104-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S113 104
104-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S114 104
105-1-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S119 105
105-5-CD34-CMPv3_EVI-pool-33_240513_A01176_BHGKWCDRX3_S120 105
106-1-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S55 106
106-5-CD34-CMPv3_EVI-pool-38_240513_A01176_BHGKWCDRX3_S56 106
USC53-1-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S107 USC53
USC53-5-CD34-CMPv3_EVI-pool-32_240513_A01176_BHGKWCDRX3_S108 USC53
9-1-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S9 9
9-5-PBGran-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S10 9
17-1-CD34Pos-CMPv3_EVI2-pool-42_241111_A00559_AHF5FFDRX5_S13 17
25-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S17 25
25-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S18 25
45-1-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S25 45
45-5-BMGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S26 45
62-1-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S27 62
62-5-PBGran-CMPv3_EVI2-pool-43_241111_A00559_AHF5FFDRX5_S28 62
71-1-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S37 71
71-5-BMGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S38 71
73-1-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S39 73
73-5-PBGran-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S40 73
80-1-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S47 80
80-5-CD34Pos-CMPv3_EVI2-pool-44_241111_A00559_AHF5FFDRX5_S48 80
93-1-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S61 93
93-5-PBGran-CMPv3_EVI2-pool-45_241111_A00559_AHF5FFDRX5_S62 93
IDs in VAFS file but not in main
x
IDs in main file but not in VAFS
x
14
96
USC60

Cumulative Clonal Growth Rates

Bookkeeping

Growth rate, 𝛼 = log (𝑉𝐴𝐹 𝑓𝑜𝑙𝑙𝑜𝑤-𝑢𝑝/𝑉𝐴𝐹 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 )/𝑡𝑖𝑚𝑒 Patients 14 and 96 have no VAF info because they did not have nay VAFS, therefore their growth rate is 0

ID before and after vdate file
Before After
1 1
1 1
1 1
2 2
2 2
2 2
2 2
2 2
3 3
3 3
3 3
3 3
3 3
4 4
4 4
4 4
4 4
4 4
5 5
5 5
5 5
5 5
5 5
6 6
6 6
6 6
6 6
6 6
7 7
7 7
7 7
7 7
7 7
8 8
8 8
8 8
8 8
8 8
9 9
9 9
9 9
9 9
9 9
10 10
10 10
10 10
10 10
10 10
11 11
11 11
11 11
11 11
11 11
12 12
12 12
13 13
13 13
13 13
13 13
13 13
14 14
14 14
14 14
14 14
14 14
15 15
15 15
15 15
15 15
15 15
16 16
16 16
16 16
16 16
16 16
17 17
18 18
18 18
18 18
18 18
18 18
19 19
19 19
19 19
19 19
19 19
20 20
20 20
20 20
20 20
20 20
21 21
22 22
22 22
22 22
22 22
22 22
23 23
23 23
23 23
24 24
24 24
24 24
24 24
24 24
25 25
25 25
25 25
25 25
25 25
26 26
26 26
26 26
26 26
26 26
27 27
27 27
27 27
27 27
27 27
28 28
28 28
28 28
28 28
28 28
29 29
29 29
29 29
29 29
29 29
30 30
30 30
30 30
30 30
30 30
31 31
31 31
31 31
31 31
31 31
32 32
33 33
33 33
33 33
34 34
34 34
34 34
34 34
35 35
35 35
35 35
35 35
35 35
36 36
36 36
36 36
36 36
36 36
37 37
37 37
37 37
37 37
37 37
38 38
38 38
38 38
38 38
38 38
39 39
39 39
39 39
39 39
39 39
40 40
40 40
40 40
40 40
40 40
41 41
41 41
41 41
41 41
41 41
42 42
42 42
42 42
42 42
42 42
43 43
44 44
44 44
45 45
45 45
45 45
45 45
45 45
46 46
46 46
46 46
46 46
46 46
47 47
47 47
47 47
47 47
47 47
48 48
49 49
49 49
49 49
49 49
49 49
50 50
50 50
50 50
50 50
50 50
51 51
51 51
51 51
51 51
51 51
62 62
62 62
62 62
62 62
62 62
63 63
63 63
63 63
63 63
63 63
64 64
64 64
64 64
64 64
64 64
65 65
65 65
65 65
66 66
66 66
66 66
66 66
66 66
67 67
67 67
67 67
67 67
67 67
68 68
68 68
68 68
68 68
68 68
69 69
69 69
69 69
69 69
69 69
70 70
70 70
70 70
70 70
70 70
71 71
71 71
71 71
71 71
71 71
72 72
72 72
72 72
72 72
72 72
73 73
73 73
73 73
73 73
73 73
74 74
74 74
74 74
75 75
75 75
75 75
75 75
75 75
76 76
77 77
77 77
77 77
77 77
77 77
78 78
78 78
78 78
78 78
79 79
79 79
79 79
79 79
79 79
80 80
80 80
80 80
80 80
80 80
81 81
81 81
82 82
83 83
83 83
83 83
83 83
83 83
84 84
84 84
84 84
84 84
84 84
85 85
85 85
85 85
85 85
85 85
86 86
86 86
86 86
86 86
86 86
87 87
88 88
88 88
88 88
88 88
88 88
89 89
89 89
89 89
89 89
89 89
90 90
90 90
90 90
90 90
90 90
91 91
91 91
91 91
91 91
91 91
92 92
92 92
92 92
92 92
92 92
93 93
93 93
93 93
93 93
93 93
94 94
94 94
94 94
94 94
94 94
95 95
95 95
95 95
95 95
95 95
96 96
96 96
96 96
96 96
96 96
97 97
97 97
97 97
97 97
97 97
98 98
98 98
98 98
98 98
98 98
99 99
99 99
99 99
99 99
99 99
100 100
100 100
100 100
100 100
100 100
101 101
101 101
101 101
101 101
101 101
102 102
102 102
102 102
102 102
102 102
103 103
103 103
104 104
104 104
104 104
104 104
104 104
105 105
105 105
105 105
105 105
105 105
106 106
106 106
106 106
106 106
106 106
AAL-01-01 AAL1
AAL-01-05 AAL1
AAL-02-01 AAL2
AAL-02-02 AAL2
AAL-03-01 AAL3
AAL-03-05 AAL3
AAL-04-01 AAL4
AAL-04-05 AAL4
AAL-05-01 AAL5
AAL-05-05 AAL5
USC-52-1 USC52
USC-52-5 USC52
USC-53-1 USC53
USC-53-5 USC53
USC-54-1 USC54
USC-54-5 USC54
USC-55-1 USC55
USC-55-5 USC55
USC-56-1 USC56
USC-56-5 USC56
USC-57-1 USC57
USC-57-5 USC57
USC-59-1 USC59
USC-59-5 USC59
USC-60-1 USC60
patients being removed from VAF analysis due to no follow-up visit
EVI2 …2 …3 …4 ID visit
17 1 Baseline 43174 17 1
21 1 Baseline 43243 21 1
32 1 Baseline 43502 32 1
43 1 Baseline 43679 43 1
48 1 Baseline 43781 48 1
76 1 Baseline 44088 76 1
82 1 Baseline 44091 82 1
87 1 Baseline 44266 87 1
USC-60-1 1 Baseline 44550 USC60 1
Stable with no VAFS
Var1 Freq
14 1
96 1
Missing baseline and FU
ID visit_1 AF_1 Time_1 Hugo_Symbol cDNA_Change visit_FU AF_FU Time_FU

Cumulative

All patients

Accounting: 109 patients, 9 with only a follow-up time, 3 without any VAF info, and 1 without either for a total of 11 patients excluded (8 no follow-up only, 2 no VAFS info only, 1 missing both)

Placebo
(N=51)
Vitamin C
(N=49)
Overall
(N=100)
GR
Mean (SD) 0.843 (3.25) 0.450 (1.98) 0.650 (2.70)
Median [Min, Max] 0.201 [-2.70, 18.4] 0.0404 [-4.69, 9.66] 0.111 [-4.69, 18.4]
emmeans and contrast
Treatment_arm emmean SE df asymp.LCL asymp.UCL
Placebo 0.3057725 0.1484876 NA 0.0147422 0.5968028
Vitamin C 0.1964945 0.1514876 NA -0.1004157 0.4934048
contrast estimate SE df asymp.LCL asymp.UCL
Placebo - Vitamin C 0.109278 0.2121251 NA -0.3064795 0.5250355
p-value on difference
model term df1 df2 F.ratio Chisq p.value
Treatment_arm 1 Inf 0.265 0.265 0.6064424

FC from rlm
FC asymp.LCL asymp.UCL
1.115472 0.7360336 1.690519

Subgroups

Bookkeeping
Counts per diagnosis main file
Var1 Freq
CCUS 36
MDS 39
MDS/MPN 23
NA 2
Patients with baseline TET2, IDH1, or IDH2 mutations
ID Time Hugo_Symbol
28 1 1 KRAS
29 1 1 TET2
30 1 1 TET2
59 10 1 SH2B3
60 10 1 SRSF2
61 10 1 IDH1
564 102 1 TET2
348 104 1 PTPN11
349 104 1 TET2
350 104 1 TET2
351 104 1 TET2
352 104 1 TET2
613 104 1 SRSF2
358 105 1 TET2
359 105 1 TET2
360 105 1 ZRSR2
361 105 1 PHF6
615 105 1 SRSF2
367 106 1 CBL
368 106 1 TET2
369 106 1 TET2
617 106 1 SRSF2
66 11 1 TET2
68 12 1 KRAS
69 12 1 SRSF2
70 12 1 RUNX1
71 12 1 KIT
72 12 1 TET2
78 13 1 TET2
79 13 1 TET2
80 13 1 TET2
81 13 1 TET2
82 13 1 TET2
83 13 1 ZRSR2
438 17 1 TP53
439 17 1 CEBPA
440 17 1 RUNX1
441 17 1 TET2
442 17 1 TET2
623 17 1 SRSF2
100 18 1 DNMT3A
101 18 1 TET2
104 19 1 TET2
105 19 1 TET2
106 19 1 ZRSR2
110 20 1 TET2
111 20 1 TET2
443 21 1 PTPN11
444 21 1 DNMT3A
445 21 1 U2AF1
446 21 1 TET2
447 21 1 TET2
448 21 1 TET2
449 21 1 TET2
115 22 1 DNMT3A
116 22 1 ASXL1
117 22 1 U2AF1
118 22 1 TET2
119 22 1 TET2
120 22 1 TET2
1 23 1 DNMT3A
2 23 1 IDH1
450 24 1 TET2
451 24 1 TET2
454 25 1 TET2
455 25 1 TET2
456 25 1 TET2
624 25 1 SRSF2
5 26 1 MPL
6 26 1 SH2B3
7 26 1 SH2B3
8 26 1 TET2
9 26 1 TET2
10 26 1 JAK2
126 28 1 DNMT3A
127 28 1 TET2
34 3 1 TET2
35 3 1 TET2
136 30 1 NF1
137 30 1 DNMT3A
138 30 1 RUNX1
139 30 1 RUNX1
140 30 1 TET2
141 30 1 TET2
142 30 1 BCOR
143 30 1 STAG2
590 30 1 SRSF2
151 31 1 SH2B3
152 31 1 TP53
153 31 1 TET2
154 31 1 ZRSR2
155 31 1 STAG2
592 31 1 SRSF2
163 33 1 TET2
169 36 1 TET2
170 36 1 TET2
594 36 1 NF1
595 36 1 SRSF2
185 41 1 IDH2
186 41 1 DNMT3A
187 41 1 DNMT3A
188 41 1 DNMT3A
189 41 1 TET2
463 42 1 TET2
198 46 1 IDH2
600 46 1 SRSF2
200 47 1 TET2
201 47 1 TET2
202 47 1 ZRSR2
203 47 1 ZRSR2
213 50 1 TET2
602 50 1 SRSF2
216 51 1 DNMT3A
217 51 1 TET2
218 51 1 TET2
219 51 1 TET2
422 6 1 DNMT3A
423 6 1 SF3B1
424 6 1 SF3B1
425 6 1 TET2
224 64 1 TP53
225 64 1 U2AF1
226 64 1 TET2
227 64 1 TET2
478 66 1 SF3B1
479 66 1 TET2
480 66 1 TET2
481 66 1 ZRSR2
231 67 1 PTPN11
232 67 1 RUNX1
233 67 1 TET2
234 67 1 TET2
235 67 1 TET2
604 67 1 SRSF2
244 69 1 ASXL1
245 69 1 ASXL1
246 69 1 TET2
247 69 1 TET2
248 69 1 EZH2
249 69 1 ZRSR2
250 69 1 ZRSR2
251 69 1 ZRSR2
486 70 1 PPM1D
487 70 1 TET2
488 70 1 TET2
489 70 1 TET2
494 71 1 TET2
495 71 1 TET2
496 71 1 TET2
497 71 1 TET2
630 71 1 SRSF2
501 73 1 KRAS
502 73 1 ASXL1
503 73 1 RUNX1
504 73 1 TET2
505 73 1 TET2
632 73 1 SRSF2
261 74 1 TET2
262 74 1 TET2
263 74 1 ZRSR2
509 75 1 DNMT3A
510 75 1 TET2
267 76 1 TET2
606 76 1 SRSF2
268 78 1 CBL
269 78 1 ASXL1
270 78 1 RUNX1
271 78 1 TET2
272 78 1 TET2
273 78 1 STAG2
44 8 1 CBL
45 8 1 CBL
46 8 1 CBL
47 8 1 ASXL1
48 8 1 U2AF1
49 8 1 TET2
50 8 1 TET2
51 8 1 BRAF
524 80 1 TET2
525 80 1 TET2
634 80 1 SRSF2
302 84 1 RUNX1
303 84 1 TET2
607 84 1 SRSF2
531 88 1 SF3B1
532 88 1 TET2
533 88 1 EZH2
314 89 1 ASXL1
315 89 1 TET2
316 89 1 TET2
317 89 1 ZRSR2
430 9 1 SH2B3
431 9 1 RUNX1
432 9 1 TET2
433 9 1 TET2
621 9 1 SRSF2
540 91 1 TET2
541 91 1 TET2
542 91 1 ZRSR2
546 92 1 SF3B1
547 92 1 TET2
550 93 1 IDH1
551 93 1 ZRSR2
552 93 1 ZRSR2
636 93 1 SRSF2
322 94 1 TET2
609 94 1 SRSF2
556 95 1 GNB1
557 95 1 DNMT3A
558 95 1 TET2
324 97 1 KRAS
325 97 1 ASXL1
326 97 1 TET2
330 98 1 MPL
331 98 1 TET2
332 98 1 TET2
373 AAL1 1 SRSF2
374 AAL1 1 IDH1
375 AAL1 1 RUNX1
379 AAL2 1 DNMT3A
380 AAL2 1 SF3B1
381 AAL2 1 ASXL1
382 AAL2 1 TET2
389 AAL4 1 TET2
390 AAL4 1 TET2
391 AAL4 1 ZRSR2
392 AAL4 1 ZRSR2
393 AAL5 1 SF3B1
394 AAL5 1 TET2
397 USC52 1 SF3B1
398 USC52 1 TET2
399 USC52 1 STAG2
402 USC53 1 TET2
403 USC53 1 TET2
404 USC53 1 TET2
405 USC53 1 TET2
406 USC53 1 ZRSR2
619 USC53 1 SRSF2
580 USC57 1 TET2
581 USC57 1 TET2
TET2 mutation status

Median baseline vitamin C mutation status

Baseline diagnosis

Individual mutations

Counts of each mutation
Var1 Freq
FLT3 1
GNB1 1
NRAS 1
PHF6 1
PPM1D 1
SETBP1 1
BCOR 2
BRAF 2
ETNK1 2
ETV6 2
GATA2 2
JAK2 2
KIT 2
MPL 2
CEBPA 3
EZH2 3
IDH2 3
NF1 3
PTPN11 3
IDH1 4
CBL 6
KRAS 6
SH2B3 6
STAG2 7
TP53 7
U2AF1 7
RUNX1 14
SF3B1 21
ASXL1 24
ZRSR2 26
SRSF2 27
DNMT3A 31
TET2 108

Emergence of a new mutation

emmeans and contrast
Treatment_arm emmean SE df asymp.LCL asymp.UCL
Placebo -1.085708 0.3263456 Inf -1.725334 -0.4460830
Vitamin C -1.114014 0.3354149 Inf -1.771416 -0.4566132
contrast estimate SE df z.ratio p.value
Placebo - Vitamin C 0.0283058 0.4734656 Inf 0.0597842 0.9523275
joint tests
model term df1 df2 F.ratio Chisq p.value
Treatment_arm 1 Inf 0.004 0.004 0.9523275
time 1 Inf 0.063 0.063 0.8010501
Placebo
(N=51)
Vitamin C
(N=49)
Overall
(N=100)
Emergent
Mean (SD) 0.255 (0.440) 0.245 (0.434) 0.250 (0.435)
Median [Min, Max] 0 [0, 1.00] 0 [0, 1.00] 0 [0, 1.00]
time
Mean (SD) 0.920 (0.296) 1.03 (0.181) 0.972 (0.251)
Median [Min, Max] 1.02 [0.235, 1.43] 1.02 [0.249, 1.33] 1.02 [0.235, 1.43]

Progressive, stable, contracting clones

Each defined as: averaging >10% over 1 year is an expanding clones, <10% contracting clones, within +/-10% stable.

Manuscript figure

Plasma Vitamin C

Manuscript Figure

Patient plasma vitamin C level. A) Composition of all patients, placebo controls, and vitamin C treated individuals with: vitamin C deficiency, inadequate vitamin C, or adequate vitamin C at inclusion; distributions are relatively similar between the two treatment arms. B) Plasma vitamin C level at each timepoint by treatment arm; p-values were estimated using robust linear mixed-effects model with a random intercept for each individual. C) LOESS smoothed vitamin C level over time with standard error ribbons. Individuals with >200 /L vitamin C level were censored in C) to better characterize dispersion among trial participants, all individual measures are shown in panel B).

Supplemental figure, Vitamin C change over time

Supplemental figure xx. Change in vitamin C over time.

Placebo
(N=54)
Vitamin C
(N=55)
Overall
(N=109)
Baseline Vitamin C
Mean (SD) 43.66 (24.55) 47.64 (25.17) 45.67 (24.83)
Median (Min, Max) 43.75 (22.20, 60.39) 45.85 (29.80, 69.12) 44.18 (27.33, 63.32)
EOT Vitamin C
Mean (SD) 45.31 (31.09) 83.22 (24.40) 65.12 (33.56)
Median (Min, Max) 48.73 (20.56, 58.21) 81.90 (67.08, 99.57) 63.82 (47.69, 87.34)
Missing 12 (22.2%) 9 (16.4%) 21 (19.3%)
change in vitamin C
Treatment_arm emmean SE df z.ratio p.value
Placebo -0.7534369 4.882218 NA -0.1543227 0.8773553
Vitamin C 36.8381243 4.665120 NA 7.8965003 0.0000000
Fold change in vitamin C
Treatment_arm response SE df asymp.LCL asymp.UCL
Placebo 0.9257738 0.0960257 NA 0.7554647 1.134477
Vitamin C 1.9340593 0.1916894 NA 1.5925941 2.348737
contrast ratio SE df asymp.LCL asymp.UCL
Placebo / Vitamin C 0.4786688 0.0686721 NA 0.3613414 0.6340922

Supplemental figure, plasma versus bone marrow vitamin C

Correlate Vitamin C in plasma and bone marrow

Spearman

Survival

Includes all samples, unadjusted. We also performed a landmark analysis and analyzed this same data with peto-peto. Both were still significant, therefore an FDR correction would not change our findings here.

Primary outcome KM (Figure 3)

Unadjusted Kaplan-Meier curves for overall survival. Estimated hazard ratio for vitamin C treated patients versus controls based on an unadjusted Cox proportional hazards regression 0.35, 95% CI 0.17, 0.71.

Placebo
(N=54)
Vitamin C
(N=55)
Overall
(N=109)
Follow up (Months)
Mean (sd) 30.6 (17.0) 39.3 (17.8) 35.0 (17.9)
Median [Q1, Q3] 28.1 [18.2, 41.2] 36.4 [25.8, 49.5] 33.6 [21.4, 48.3]
Event
Censored 30 (55.6%) 44 (80.0%) 74 (67.9%)
Died 24 (44.4%) 11 (20.0%) 35 (32.1%)

Hazard ratio and CI
exp(coef) exp(-coef) lower .95 upper .95
Treatment_armVitamin C 0.3473816 2.878679 0.1697418 0.7109265

Cox model (No interaction)

Supplemntal figure XX. Forest plot for adjusted Cox model. Cox proportional hazards regression to estimated efficacy of vitamin C on overall survival was adjusted for patient age at inclusion, gender, hemoglobin levels at inclusion, and whether or not they had been diagnosed with CCUS.

Cox model (Age interaction)

Supplemental figure XX. Forest plot for adjusted Cox model in age interaction. Cox proportional hazards regression to estimated efficacy of vitamin C as a function of age. Age was mean centered and converted to decades to improve hazard ratio scales. Overall vitamin C was still effective, with evidence that it’s efficacy decreases with age.

Cox model (TET interaction)

Placebo Vitamin C
TET2Mut 32 31
TET2neg 22 24

Cox model (Hb1 interaction)

Cox model (Sex interaction)

Cox model (CCUS interaction)

Forest plot cannot be made due to diverging SE in treatment

## Call:
## coxph(formula = Surv(Days_FU_OS, FU_Death) ~ VitaminC + age_c + 
##     vitc_ccus + Male + Hb1_c + CCUS, data = df)
## 
##                       coef        exp(coef)         se(coef)      z        p
## VitaminC    -0.48013788583    0.61869807622    0.39738120115 -1.208 0.226949
## age_c        0.04289957950    1.04383306735    0.02439246075  1.759 0.078625
## vitc_ccus  -18.85453900918    0.00000000648 5424.03021304527 -0.003 0.997226
## Male         0.84285200671    2.32298270049    0.46551028687  1.811 0.070203
## Hb1_c       -0.67791720098    0.50767327337    0.18565236465 -3.652 0.000261
## CCUS         0.23284559292    1.26218657373    0.51029109759  0.456 0.648175
## 
## Likelihood ratio test=40.98  on 6 df, p=0.0000002919
## n= 109, number of events= 35

Cox model (baseline vitamin C interaction)

2-year landmark

Maybe Figure? A 2 year landmark analysis was performed to determine if there was still evidence of vitamin C efficacy after removing individuals who had events prior to 2 years. This landmark analysis ensures the effects of vitamin C had sufficient time to reach efficacy.

Removed from landmark
ID Days_FU_OS FU_Death Treatment_arm
9 531 1 Vitamin C
12 403 1 Placebo
17 113 1 Vitamin C
23 360 1 Placebo
27 606 1 Vitamin C
30 621 1 Vitamin C
33 646 1 Placebo
35 683 1 Placebo
37 379 1 Placebo
42 618 1 Placebo
44 132 1 Placebo
65 235 1 Placebo
73 413 1 Placebo
78 479 1 Placebo
81 250 1 Placebo
83 578 1 Vitamin C
87 391 1 Placebo
95 701 0 Placebo
96 666 0 Vitamin C
97 658 0 Placebo
98 650 0 Vitamin C
99 650 0 Vitamin C
100 608 0 Vitamin C
101 594 0 Placebo
102 539 0 Placebo
103 152 1 Vitamin C
104 462 0 Vitamin C
105 401 0 Vitamin C
106 364 0 Placebo
AAL2 509 1 Placebo
AAL5 386 0 Placebo
USC53 695 1 Placebo
USC59 714 0 Placebo
USC60 1 0 Placebo

Per patient protocol

likelihood ratio test p-value is nearly identical to log-rank

IDs removed from main
x
1
12
17
21
23
30
32
33
35
37
43
44
48
65
72
74
76
78
81
82
87
96
103
AAL2
AAL4

LRT on treatment
#Df LogLik Df Chisq Pr(>Chisq)
1 -76.00080 NA NA NA
0 -77.16977 -1 2.337937 0.1262567

Subgroups (suppl)

All subgroup analyses include only the hazard ratio with 95% CI as these are exploratory.

TET1 or IDH1/2 at baseline

Supplemental Figure XX. Overall survival by TET2 or IDH1/2 mutation status. Hazard ratio and confidence intervals were estimated using Cox proportional hazards models on data stratified by TET2 and IDH1/2 mutation status. Survival curves and estimates are consistent with the primary outcome.

LRT for interaction
#Df LogLik Df Chisq Pr(>Chisq)
3 -142.8280 NA NA NA
2 -143.5895 -1 1.523109 0.2171495

Manuscript Figure

LOF TET2

AKA TET2 hypermethylation vs WT signature

LRT for interaction
#Df LogLik Df Chisq Pr(>Chisq)
3 -107.0926 NA NA NA
2 -107.8713 -1 1.557548 0.2120246

Above/Below median Vitamin C

Supplemental figure XX. Overall survival by vitamin C above or below median vitamin C at inclusion. Hazard ratio and confidence intervals were estimated using Cox proportional hazards models on data stratified by patients with plasma vitamin C level below the median measure at inclusion, and greater than or equal to the median. Results are consistent with the primary outcome.

LRT for interaction
#Df LogLik Df Chisq Pr(>Chisq)
3 -142.7831 NA NA NA
2 -142.7974 -1 0.0284974 0.8659447

Diagnostic subgroup

Supplemental figure XX. Overall survival by diagnostic subgroup at inclusion. Hazard ratio and confidence intervals were estimated using Cox proportional hazards models on data stratified by diagnosis at inclusion. CCUS appears to be a subgroup that can benefit particularly well from vitamin C supplementation.

LRT for interaction
#Df LogLik Df Chisq Pr(>Chisq)
11 -134.4270 NA NA NA
6 -138.5647 -5 8.275447 0.1416943

Competing risk regression (progression)

For this analysis death is a competing risk of high-risk progression. We are a bit limited in sample size and events; there are only 14 progression events. Power to detect any differences in progression is quite low and we will have difficulty adjusting for any covariates here. We see corroboration with our overall survival findings that death (the dotted lines) are significantly different, however we do not have enough evidence to determine if progression also differs.

Global Methylation

Figure XX. Global methylation changes over time by treatment arm A) 5-mC/dG and B) 5-hmC/5-mC level for each patient at inclusion and end-of-therapy (EOT) and the change in these measures between inclusion and EOT. Data were analyzed using robust linear mixed-effects models with a random intercept for each patient and an interaction between treatment and time point to assess if measures changed differently over time. Models also included a covariate for batch.

Methylation IDs not in Mass Spec data
x
75
79
6
5
4
26
47
23
93

Delta 5-mC and 5-hmC/5-mC

TET2

baseline vitamin C

Diagnosis

Baseline 5-mC and 5-hmC/5-mC

The raw p-values should be printing in each section

Saved p-values and FDR adjustments
outcome subgroup p FDR
mC.dG TET2 0.1991000 0.2844286
mC.dG vitc_med 0.1066000 0.2132000
mC.dG vitc_ccus 0.0078000 0.0390000
mC.dG vitc_ccus 0.6186000 0.6873333
mC.dG vitc_ccus 0.0797000 0.2092500
hmC.mC TET2 0.0000001 0.0000009
hmC.mC vitc_med 0.5790000 0.6873333
hmC.mC vitc_ccus 0.7838000 0.7838000
hmC.mC vitc_ccus 0.1405000 0.2341667
hmC.mC vitc_ccus 0.0837000 0.2092500

TET2

baseline vitamin C

Diagnosis

5-mC/dG

All corr

##            
##             All
##   Placebo    45
##   Vitamin C  40

TET2

##            
##             No TET2 or IDH1/2 mutation TET2 or IDH1/2 mutation
##   Placebo                           16                      29
##   Vitamin C                         18                      22

LOF TET2

##            
##             TET2 WT signature TET2 hypermethylation signature
##   Placebo                  25                              15
##   Vitamin C                21                              14

Median Vitamin C

##            
##             Below median Above median
##   Placebo             23           22
##   Vitamin C           19           21

Vitamin C Severe

##            
##             Severe (< 11.4 μmol/L) All others
##   Placebo                        4         41
##   Vitamin C                      2         38

Diagnosis (CCUS)

##            
##             CCUS MDS MDS/MPN
##   Placebo     16  17      11
##   Vitamin C   15  17       7

5-hmC/dG

All corr

##            
##             All
##   Placebo    45
##   Vitamin C  40

TET2

##            
##             No TET2 or IDH1/2 mutation TET2 or IDH1/2 mutation
##   Placebo                           16                      29
##   Vitamin C                         18                      22

LOF TET2

##            
##             TET2 WT signature TET2 hypermethylation signature
##   Placebo                  25                              15
##   Vitamin C                21                              14

Median Vitamin C

##            
##             Below median Above median
##   Placebo             23           22
##   Vitamin C           19           21

Vitamin C Severe

##            
##             Severe (< 11.4 μmol/L) All others
##   Placebo                        4         41
##   Vitamin C                      2         38

Diagnosis (CCUS)

##            
##             CCUS MDS MDS/MPN
##   Placebo     16  17      11
##   Vitamin C   15  17       7

5-hmC/5-mC

All corr

##            
##             All
##   Placebo    45
##   Vitamin C  40

TET2

##            
##             No TET2 or IDH1/2 mutation TET2 or IDH1/2 mutation
##   Placebo                           16                      29
##   Vitamin C                         18                      22

LOF TET2

##            
##             TET2 WT signature TET2 hypermethylation signature
##   Placebo                  25                              15
##   Vitamin C                21                              14

Median Vitamin C

##            
##             Below median Above median
##   Placebo             23           22
##   Vitamin C           19           21

Vitamin C Severe

##            
##             Severe (< 11.4 μmol/L) All others
##   Placebo                        4         41
##   Vitamin C                      2         38

Diagnosis (CCUS)

##            
##             CCUS MDS MDS/MPN
##   Placebo     16  17      11
##   Vitamin C   15  17       7

Manuscript Figure

rlmer estimates 5mC/dG
Estimate Std. Error t value 2.5% 97.5%
(Intercept) 0.0352878 0.0010852 32.5174893 0.0331609 0.0374147
Treatment_armVitamin C 0.0004736 0.0007077 0.6692364 -0.0009135 0.0018608
TimepointEOT -0.0000521 0.0003274 -0.1590705 -0.0006938 0.0005896
Batch 0.0009001 0.0006899 1.3047354 -0.0004520 0.0022523
Treatment_armVitamin C:TimepointEOT -0.0004371 0.0004760 -0.9183844 -0.0013700 0.0004957
Time comparisons by treatment 5mC/dG
Timepoint Treatment_arm emmean SE df asymp.LCL asymp.UCL
Baseline Placebo 0.0366380 0.0005055 Inf 0.0356473 0.0376287
EOT Placebo 0.0365859 0.0005122 Inf 0.0355819 0.0375899
Baseline Vitamin C 0.0371116 0.0005036 Inf 0.0361245 0.0380987
EOT Vitamin C 0.0366224 0.0005234 Inf 0.0355966 0.0376483
contrast Treatment_arm estimate SE df z.ratio p.value
Baseline - EOT Placebo 0.0000521 0.0003274 Inf 0.1590705 0.8736133
Baseline - EOT Vitamin C 0.0004892 0.0003457 Inf 1.4149172 0.1570928
anova on 5mC/dG model
model term df1 df2 F.ratio Chisq p.value
1 Treatment_arm 1 Inf 0.143 0.143 0.7057041
3 Timepoint 1 Inf 1.291 1.291 0.2558292
4 Batch 1 Inf 1.702 1.702 0.1919830
2 Treatment_arm:Timepoint 1 Inf 0.843 0.843 0.3584176
Baseline
EOT
Overall
Placebo
(N=48)
Vitamin C
(N=48)
Placebo
(N=45)
Vitamin C
(N=40)
Placebo
(N=93)
Vitamin C
(N=88)
mC.dG
Mean (SD) 0.0365 (0.00461) 0.0369 (0.00330) 0.0363 (0.00416) 0.0362 (0.00373) 0.0364 (0.00437) 0.0366 (0.00350)
Median [Min, Max] 0.0363 [0.0264, 0.0560] 0.0376 [0.0265, 0.0452] 0.0372 [0.0251, 0.0436] 0.0367 [0.0286, 0.0443] 0.0367 [0.0251, 0.0560] 0.0373 [0.0265, 0.0452]
rlmer estimates 5hmC/5mC
Estimate Std. Error t value 2.5% 97.5%
(Intercept) 0.0067577 0.0008970 7.5339083 0.0049996 0.0085157
Treatment_armVitamin C -0.0002895 0.0005735 -0.5047597 -0.0014134 0.0008345
TimepointEOT -0.0001792 0.0001756 -1.0205230 -0.0005234 0.0001650
Batch 0.0002108 0.0005732 0.3677627 -0.0009127 0.0013343
Treatment_armVitamin C:TimepointEOT -0.0000737 0.0002557 -0.2884575 -0.0005748 0.0004274
Time comparisons by treatment 5hmC/5mC
Timepoint Treatment_arm emmean SE df asymp.LCL asymp.UCL
Baseline Placebo 0.0070739 0.0004098 Inf 0.0062707 0.0078770
EOT Placebo 0.0068947 0.0004123 Inf 0.0060865 0.0077028
Baseline Vitamin C 0.0067844 0.0004082 Inf 0.0059843 0.0075845
EOT Vitamin C 0.0065315 0.0004157 Inf 0.0057168 0.0073461
contrast Treatment_arm estimate SE df z.ratio p.value
Baseline - EOT Placebo 0.0001792 0.0001756 Inf 1.020523 0.3074805
Baseline - EOT Vitamin C 0.0002529 0.0001859 Inf 1.360685 0.1736134
anova on 5hmC/5mC model
model term df1 df2 F.ratio Chisq p.value
1 Treatment_arm 1 Inf 0.337 0.337 0.5616665
3 Timepoint 1 Inf 2.855 2.855 0.0910993
4 Batch 1 Inf 0.135 0.135 0.7130502
2 Treatment_arm:Timepoint 1 Inf 0.083 0.083 0.7729965
Baseline
EOT
Overall
Placebo
(N=48)
Vitamin C
(N=48)
Placebo
(N=45)
Vitamin C
(N=40)
Placebo
(N=93)
Vitamin C
(N=88)
hmC.mC
Mean (SD) 0.00711 (0.00266) 0.00697 (0.00276) 0.00673 (0.00265) 0.00686 (0.00243) 0.00693 (0.00265) 0.00692 (0.00260)
Median [Min, Max] 0.00617 [0.00206, 0.0130] 0.00634 [0.00342, 0.0138] 0.00616 [0.00161, 0.0128] 0.00666 [0.00370, 0.0146] 0.00616 [0.00161, 0.0130] 0.00651 [0.00342, 0.0146]

Cytokines

Primary Analysis, all patients

Suppl all cytokines

Supplemental Figure XX. log2 fold-change in cytokine measures for all individuals. Data were analyzed using robust linear mixed-effects models with a random intercept for each patient and an interaction between treatment and timepoint to assess if measures changed differently over time.

Significant changes over time by treatment
assay contrast Treatment_arm estimate SE df z.ratio p.value FDR FoldChange
G-CSF Baseline - EOT Placebo -0.1743696 0.0519787 Inf -3.3546344 0.0007947 0.0037748 1.1284712
G-CSF Baseline - EOT Vitamin C 0.1876696 0.0526599 Inf 3.5638023 0.0003655 0.0019843 0.8780229
M-CSF Baseline - EOT Placebo -0.2528030 0.0328338 Inf -7.6994741 0.0000000 0.0000000 1.1915198
M-CSF Baseline - EOT Vitamin C -0.0492938 0.0332663 Inf -1.4817929 0.1383954 0.3578402 1.0347583
SDF-1α Baseline - EOT Placebo -0.1117457 0.0299780 Inf -3.7275946 0.0001933 0.0012243 1.0805349
SDF-1α Baseline - EOT Vitamin C -0.0339439 0.0303702 Inf -1.1176700 0.2637080 0.5203999 1.0238071
IL-8_HA Baseline - EOT Placebo 0.0042498 0.1529807 Inf 0.0277798 0.9778378 0.9778378 0.9970586
IL-8_HA Baseline - EOT Vitamin C 0.0258342 0.1550253 Inf 0.1666448 0.8676496 0.9158523 0.9822525
IP-10 Baseline - EOT Placebo -0.2087999 0.0477696 Inf -4.3709833 0.0000124 0.0001567 1.1557264
IP-10 Baseline - EOT Vitamin C 0.0196664 0.0490919 Inf 0.4006031 0.6887124 0.7697374 0.9864608
GM-CSF Baseline - EOT Placebo -0.1400681 0.1612918 Inf -0.8684141 0.3851677 0.5854549 1.1019571
GM-CSF Baseline - EOT Vitamin C 0.1078295 0.1630937 Inf 0.6611506 0.5085157 0.6475787 0.9279832
IL-1α Baseline - EOT Placebo 0.1326469 0.1872146 Inf 0.7085283 0.4786173 0.6475787 0.9121564
IL-1α Baseline - EOT Vitamin C -0.3528312 0.1893061 Inf -1.8638129 0.0623480 0.1875775 1.2770643
IL-7 Baseline - EOT Placebo -0.0437187 0.0496925 Inf -0.8797848 0.3789759 0.5854549 1.0307674
IL-7 Baseline - EOT Vitamin C -0.0364710 0.0506757 Inf -0.7196941 0.4717134 0.6475787 1.0256020
VEGF_cyto Baseline - EOT Placebo -0.0815753 0.0440712 Inf -1.8509883 0.0641712 0.1875775 1.0581729
VEGF_cyto Baseline - EOT Vitamin C -0.0491619 0.0449321 Inf -1.0941374 0.2738947 0.5203999 1.0346637
IFN-γ Baseline - EOT Placebo -0.0916601 0.0916500 Inf -1.0001106 0.3172570 0.5740841 1.0655956
IFN-γ Baseline - EOT Vitamin C 0.1292400 0.0940747 Inf 1.3738017 0.1695033 0.3578402 0.9143130
IL-10 Baseline - EOT Placebo -0.2665197 0.0707810 Inf -3.7654125 0.0001663 0.0012243 1.2029025
IL-10 Baseline - EOT Vitamin C 0.1065271 0.0726644 Inf 1.4660161 0.1426439 0.3578402 0.9288212
IL-12p70 Baseline - EOT Placebo 0.0666808 0.0757469 Inf 0.8803108 0.3786910 0.5854549 0.9548323
IL-12p70 Baseline - EOT Vitamin C 0.1923139 0.0776949 Inf 2.4752432 0.0133145 0.0505953 0.8752009
IL-17 Baseline - EOT Placebo -0.1301076 0.0924251 Inf -1.4077087 0.1592173 0.3578402 1.0943753
IL-17 Baseline - EOT Vitamin C 0.0604126 0.0948707 Inf 0.6367888 0.5242624 0.6475787 0.9589898
IL-1β Baseline - EOT Placebo -0.0080323 0.1924598 Inf -0.0417348 0.9667101 0.9778378 1.0055831
IL-1β Baseline - EOT Vitamin C -0.1026983 0.1970958 Inf -0.5210578 0.6023265 0.6935881 1.0737799
IL-4 Baseline - EOT Placebo -0.2480545 0.1781690 Inf -1.3922428 0.1638489 0.3578402 1.1876045
IL-4 Baseline - EOT Vitamin C -0.0666929 0.1827328 Inf -0.3649749 0.7151301 0.7764270 1.0473132
IL-6 Baseline - EOT Placebo -0.4355809 0.0822540 Inf -5.2955589 0.0000001 0.0000023 1.3524553
IL-6 Baseline - EOT Vitamin C 0.0532411 0.0844264 Inf 0.6306218 0.5282879 0.6475787 0.9637687
TNF-α Baseline - EOT Placebo -0.1323477 0.0595905 Inf -2.2209543 0.0263541 0.0910413 1.0960759
TNF-α Baseline - EOT Vitamin C 0.0537205 0.0611725 Inf 0.8781813 0.3798453 0.5854549 0.9634485
RANTES Baseline - EOT Placebo 0.0555723 0.0952164 Inf 0.5836425 0.5594608 0.6643597 0.9622127
RANTES Baseline - EOT Vitamin C -0.3102476 0.0977680 Inf -3.1733040 0.0015071 0.0063635 1.2399205
TGF-β1 Baseline - EOT Placebo -0.0286679 0.0425698 Inf -0.6734335 0.5006716 0.6475787 1.0200698
TGF-β1 Baseline - EOT Vitamin C -0.1645150 0.0436554 Inf -3.7684954 0.0001642 0.0012243 1.1207892
Cytokines that changed differently over time for Placebo versus Vitamin C
assay p est se FDR
1 G-CSF 0.0000010 0.3620392 0.0739923 0.0000189
2 M-CSF 0.0000134 0.2035091 0.0467409 0.0001270
5 IP-10 0.0008518 0.2284663 0.0684978 0.0032369
11 IL-10 0.0002355 0.3730469 0.1014400 0.0011187
16 IL-6 0.0000337 0.4888220 0.1178709 0.0002133
18 RANTES 0.0073504 -0.3658199 0.1364725 0.0232761

Cytokine figure

Supplemental Figure XX. log2 fold-change in cytokine measures that changed significantly. Data were analyzed using robust linear mixed-effects models with a random intercept for each patient and an interaction between treatment and timepoint to assess if measures changed differently over time. Larger points indicate the mean log2(fold-change) with 95% CI error bars. Scales were limited to +/-1.5 log2(fold-change) to better characterize dispersion, all data points are shown in supplemental figure XX. P-values were false discovery rate adjusted using Benjamini-Hochberg.

assay Treatment_arm FoldChange FC.CI Median change IQR Q1 Q3
7 IL-6 Placebo 1.3524553 1.21, 1.51 978.7228275 4825.271944 -547.8988763 4277.373068
8 Vitamin C 0.9637687 0.86, 1.08 -305.2321957 2914.539854 -2108.8462637 805.693590
5 IL-10 Placebo 1.2029025 1.09, 1.32 48.3126753 560.975421 -64.9184297 496.056992
6 Vitamin C 0.9288212 0.84, 1.03 -48.4402901 366.301656 -225.0746532 141.227002
3 G-CSF Placebo 1.1284712 1.05, 1.21 0.3595211 7.581336 -1.5821809 5.999155
4 Vitamin C 0.8780229 0.82, 0.94 -0.9363409 5.804647 -4.5238150 1.280832
9 M-CSF Placebo 1.1915198 1.14, 1.25 1.9633393 3.361131 0.7072681 4.068399
10 Vitamin C 1.0347583 0.99, 1.08 0.4335928 3.483504 -1.5130604 1.970444
1 CXCL10 (IP-10) Placebo 1.1557264 1.08, 1.23 97.4263341 380.265155 -12.0727578 368.192398
2 Vitamin C 0.9864608 0.92, 1.05 -26.4342630 342.846245 -202.3496241 140.496621
11 RANTES (CCL5) Placebo 0.9622127 0.85, 1.1 -47.1448291 2897.441686 -1427.1604226 1470.281263
12 Vitamin C 1.2399205 1.09, 1.42 337.3523208 3489.165477 -1355.5910368 2133.574440

Volcano plots of each subroup by assay

Subgroup plots

All subgroups

95% CIs for subgroup comparisons

TET2

Showing only those with FDR < 0.1

## 
## 
## |Var1      |Var2           |Var3                        | Freq|
## |:---------|:--------------|:---------------------------|----:|
## |Placebo   |G-CSF          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |G-CSF          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |IL-10          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |IL-10          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |IL-6           |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |IL-6           |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |CXCL10 (IP-10) |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |CXCL10 (IP-10) |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |M-CSF          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |M-CSF          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |TGF-β1         |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |TGF-β1         |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |TNF-α          |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |TNF-α          |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |VEGF           |No TET2 or IDH1/2 mutations |   22|
## |Vitamin C |VEGF           |No TET2 or IDH1/2 mutations |   23|
## |Placebo   |G-CSF          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |G-CSF          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |IL-10          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |IL-10          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |IL-6           |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |IL-6           |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |CXCL10 (IP-10) |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |CXCL10 (IP-10) |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |M-CSF          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |M-CSF          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |TGF-β1         |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |TGF-β1         |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |TNF-α          |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |TNF-α          |TET2 or IDH1/2 mutation     |   31|
## |Placebo   |VEGF           |TET2 or IDH1/2 mutation     |   32|
## |Vitamin C |VEGF           |TET2 or IDH1/2 mutation     |   31|

Median Vitamin C
## 
## 
## |Var1      |Var2           |Var3                   | Freq|
## |:---------|:--------------|:----------------------|----:|
## |Placebo   |G-CSF          |Below median vitamin C |   28|
## |Vitamin C |G-CSF          |Below median vitamin C |   26|
## |Placebo   |IL-10          |Below median vitamin C |   28|
## |Vitamin C |IL-10          |Below median vitamin C |   26|
## |Placebo   |IL-6           |Below median vitamin C |   28|
## |Vitamin C |IL-6           |Below median vitamin C |   26|
## |Placebo   |CXCL10 (IP-10) |Below median vitamin C |   28|
## |Vitamin C |CXCL10 (IP-10) |Below median vitamin C |   26|
## |Placebo   |M-CSF          |Below median vitamin C |   28|
## |Vitamin C |M-CSF          |Below median vitamin C |   26|
## |Placebo   |RANTES (CCL5)  |Below median vitamin C |   28|
## |Vitamin C |RANTES (CCL5)  |Below median vitamin C |   26|
## |Placebo   |TGF-β1         |Below median vitamin C |   28|
## |Vitamin C |TGF-β1         |Below median vitamin C |   26|
## |Placebo   |G-CSF          |Above median vitamin C |   26|
## |Vitamin C |G-CSF          |Above median vitamin C |   28|
## |Placebo   |IL-10          |Above median vitamin C |   26|
## |Vitamin C |IL-10          |Above median vitamin C |   28|
## |Placebo   |IL-6           |Above median vitamin C |   26|
## |Vitamin C |IL-6           |Above median vitamin C |   28|
## |Placebo   |CXCL10 (IP-10) |Above median vitamin C |   26|
## |Vitamin C |CXCL10 (IP-10) |Above median vitamin C |   28|
## |Placebo   |M-CSF          |Above median vitamin C |   26|
## |Vitamin C |M-CSF          |Above median vitamin C |   28|
## |Placebo   |RANTES (CCL5)  |Above median vitamin C |   26|
## |Vitamin C |RANTES (CCL5)  |Above median vitamin C |   28|
## |Placebo   |TGF-β1         |Above median vitamin C |   26|
## |Vitamin C |TGF-β1         |Above median vitamin C |   28|

Diagnosis
## 
## 
## |Var1      |Var2           |Var3    | Freq|
## |:---------|:--------------|:-------|----:|
## |Placebo   |G-CSF          |CCUS    |   17|
## |Vitamin C |G-CSF          |CCUS    |   20|
## |Placebo   |IL-10          |CCUS    |   17|
## |Vitamin C |IL-10          |CCUS    |   20|
## |Placebo   |IL-1α          |CCUS    |   17|
## |Vitamin C |IL-1α          |CCUS    |   20|
## |Placebo   |IL-6           |CCUS    |   17|
## |Vitamin C |IL-6           |CCUS    |   20|
## |Placebo   |CXCL10 (IP-10) |CCUS    |   17|
## |Vitamin C |CXCL10 (IP-10) |CCUS    |   20|
## |Placebo   |M-CSF          |CCUS    |   17|
## |Vitamin C |M-CSF          |CCUS    |   20|
## |Placebo   |SDF-1α         |CCUS    |   17|
## |Vitamin C |SDF-1α         |CCUS    |   20|
## |Placebo   |G-CSF          |MDS     |   22|
## |Vitamin C |G-CSF          |MDS     |   18|
## |Placebo   |IL-10          |MDS     |   22|
## |Vitamin C |IL-10          |MDS     |   18|
## |Placebo   |IL-1α          |MDS     |   22|
## |Vitamin C |IL-1α          |MDS     |   18|
## |Placebo   |IL-6           |MDS     |   22|
## |Vitamin C |IL-6           |MDS     |   18|
## |Placebo   |CXCL10 (IP-10) |MDS     |   22|
## |Vitamin C |CXCL10 (IP-10) |MDS     |   18|
## |Placebo   |M-CSF          |MDS     |   22|
## |Vitamin C |M-CSF          |MDS     |   18|
## |Placebo   |SDF-1α         |MDS     |   22|
## |Vitamin C |SDF-1α         |MDS     |   18|
## |Placebo   |G-CSF          |MDS/MPN |   13|
## |Vitamin C |G-CSF          |MDS/MPN |   15|
## |Placebo   |IL-10          |MDS/MPN |   13|
## |Vitamin C |IL-10          |MDS/MPN |   15|
## |Placebo   |IL-1α          |MDS/MPN |   13|
## |Vitamin C |IL-1α          |MDS/MPN |   15|
## |Placebo   |IL-6           |MDS/MPN |   13|
## |Vitamin C |IL-6           |MDS/MPN |   15|
## |Placebo   |CXCL10 (IP-10) |MDS/MPN |   13|
## |Vitamin C |CXCL10 (IP-10) |MDS/MPN |   15|
## |Placebo   |M-CSF          |MDS/MPN |   13|
## |Vitamin C |M-CSF          |MDS/MPN |   15|
## |Placebo   |SDF-1α         |MDS/MPN |   13|
## |Vitamin C |SDF-1α         |MDS/MPN |   15|

Correlogram